 |
|
Raloxifene and Risk of Cardiovascular Events
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Dr Barrett-Connor and colleagues1 concluded that 4 years of postmenopausal raloxifene
therapy significantly reduces the risk of cardiovascular events in women who
are at increased risk. Several aspects of the authors' classification scheme,
however, limit the validity of their findings.
The criteria used to create a subset of women "with increased cardiovascular
risk"1 seem arbitrary and prone to incorrect
risk stratification. I believe that it is inappropriate, for instance, that
women with diabetes mellitus received as much as 75% of the points as did
women with prior myocardial infarction, especially given the nonstandard definitions
used to classify certain risk factors, such as diabetes, used in this study.
The rationale for the point system is not justified either in this study or
in the referenced article,2 which uses a
slightly different system.
Nonstandard definitions for risk factors may affect the conclusions.
For example, the authors' definition of diabetes . . . [Full Text of this Article]
RELATED ARTICLES
Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial
Elizabeth Barrett-Connor, Deborah Grady, Andreas Sashegyi, Pamela W. Anderson, David A. Cox, Krzysztof Hoszowski, Pentti Rautaharju, Kristine D. Harper, and for the MORE Investigators
JAMA. 2002;287(7):847-857.
ABSTRACT
| FULL TEXT
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
JAMA. 2001;285(19):2486-2497.
EXTRACT
| FULL TEXT
|
